PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsHydroxyamphetamine
Hydroxyamphetamine
Paredrine, Paremyd (hydroxyamphetamine) is a small molecule pharmaceutical. Hydroxyamphetamine was first approved as Paredrine on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydroxyamphetamine hydrobromide
+
Tropicamide
Tradename
Company
Number
Date
Products
PAREMYDEpic PharmaN-019261 DISCN1992-01-30
1 products, RLD
Hide discontinued
Hydroxyamphetamine hydrobromide
Tradename
Company
Number
Date
Products
PAREDRINEPharmicsN-000004 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
paremydNew Drug Application2022-09-14
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
keratitis—D007634H16
iritisEFO_1000997D007500—
iridocyclitis—D015863H20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
385 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Vitamin d deficiencyD014808EFO_0003762E55633154772
Ocular hypertensionD009798EFO_1001069H40.01954220
GlaucomaD005901EFO_0000516H401954220
HypertensionD006973EFO_0000537I101952319
Open-angle glaucomaD005902EFO_0004190H40.1—743317
Chronic renal insufficiencyD051436—N1821—2712
Kidney diseasesD007674EFO_0003086N0821—2712
Covid-19D000086382—U07.12211610
Healthy volunteers/patients———4111310
HypotensionD007022EFO_0005251I951232310
Show 50 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G20322—28
SyndromeD013577———21—47
Breast neoplasmsD001943EFO_0003869C50121—47
Papillomavirus infectionsD030361———43——7
OsteoporosisD010024EFO_0003882M81.0——2—46
Type 2 diabetes mellitusD003924EFO_0001360E11121—15
InfectionsD007239EFO_0000544——12—25
Pure autonomic failureD054970————3—14
DepressionD003863—F33.9—11—24
Shy-drager syndromeD012791EFO_1001050—111—13
Show 30 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neoplasm metastasisD009362EFO_0009708—12——25
SchizophreniaD012559EFO_0000692F2011——24
Colonic neoplasmsD003110—C1831——14
Psychotic disordersD011618—F20.81—1——23
AdenocarcinomaD000230——22———3
Hiv infectionsD015658EFO_0000764B2012——13
PainD010146EFO_0003843R52—1——23
Temporomandibular joint disordersD013705—M26.611——23
Temporomandibular joint dysfunction syndromeD013706——11——23
HypoxiaD000860—R09.02—1——12
Show 59 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Frontotemporal dementiaD057180—G31.01———12
Primary progressive aphasiaD018888EFO_0009053G31.011———12
Pick disease of the brainD020774EFO_0003096G31.011———12
Liver neoplasmsD008113EFO_1001513C22.01———12
Malabsorption syndromesD008286EFO_0009554K901————1
GastroenteritisD005759EFO_1001463K52.91————1
Crohn diseaseD003424EFO_0000384K501————1
Mucinous adenocarcinomaD002288——1————1
Rectal neoplasmsD012004——1————1
CystadenocarcinomaD003536——1————1
Show 9 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PeriodontitisD010518EFO_0000649K05.3————66
InfertilityD007246EFO_0000545—————55
Premature birthD047928EFO_0003917O60————44
Inflammatory bowel diseasesD015212EFO_0003767—————44
Low back painD017116—M54.5————44
Back painD001416—M54————44
AnemiaD000740EFO_0004272D64.9————33
Brain injuriesD001930—S06.9————33
Cognitive dysfunctionD060825—G31.84————33
Periodontal diseasesD010510—K05.6————33
Show 183 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHydroxyamphetamine
INNhydroxyamfetamine
Description
4-(2-aminopropyl)phenol is a member of amphetamines.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(N)Cc1ccc(O)cc1
Identifiers
PDB—
CAS-ID103-86-6
RxCUI—
ChEMBL IDCHEMBL1546
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDFQR280JW2N (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,972 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
42 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use